Diatech Pharmacogenetics Srl.SA.B50Diatech Pharmacogenetics is an Italian company specializing in the development, production, and commercialization of molecular diagnostic tools for precision oncology medicine.
Founded in 1996 Diatech has over 25 years of expertise in the molecular diagnostics market with focus in oncology. The company offers comprehensive solutions that simplify complex molecular diagnostic procedures into user-friendly, end-to-end workflows—from nucleic acid extraction and molecular analysis to final reporting.
Diatech’s product portfolio includes CE-IVD diagnostic kits designed to identify gene mutations and genetic variations that influence patient responses to specific cancer treatments, enhancing the effectiveness of precision medicine. As a market leader in Europe and Southeast Asia and Nord Africa , the company has experienced significant growth, becoming a key player in oncology diagnostics.
In 2025, Diatech expanded its collaboration with Merck to improve patient access to personalized medicine in the Middle East and Africa, reinforcing its commitment to global healthcare solutions. Additionally, the company announced a new partnership with Johnson & Johnson to advance precision testing (with a focus on bladder cancer) in oncology, further solidifying its position as a leader in the field.
